Radiopharmaceuticals developed for 89Zr-Immuno-PET
AbstractThe development of molecular imaging agents used for imaging of cancer tissue is of great importance for the early detection of cancer. Positron emission tomography (PET) radiopharmaceuticals consists of a positron-emitting radionuclide and a molecularstructure.89Zr-labeled monoclonal antibodies (mAbs), peptides, nanoparticles, proteins, and other compounds are called89Zr-Immuno-PET and are used in cancer tissue imaging. This review provides a general overview of the potential of molecules labeled with89Zr radionuclide, which is chosen due to its long half-life, in preclinical and clinical studies. In light of these studies, radiopharmaceuticals created using nanoparticles have greater potential than those using antibodies.
Source: Journal of Radioanalytical and Nuclear Chemistry - Category: Nuclear Medicine Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Nanotechnology | Nuclear Medicine | PET Scan | Study